Chai Discovery
Worth-Joining Index · Scorecard
v2.1 ALPHA · 2026-08Career Score
—/100
Coverage
51%
Verified
0%
Stage cohort
Early
Vibe Check
🎪 community voting coming soon
Latest valuation
$3.8B-money (Series C, 2026-07)
Total raised
~$600M total raised (through Series C, 2026-07)
Traction · Key numbers
Funding
Total raised
~$600M total raised (through Series C, 2026-07)
Rounds
3
Valuation pace
Valuation went from $1.3B to $3.8B in 7 months
$400M
Series C · 2026-07 · valuation $3.8B post-money (Series C, 2026-07) · led by Index Ventures
With: Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital · Just 7 months after Series B, valuation nearly tripled
$130M
Series B · 2025-12 · valuation $1.3B · led by General Catalyst, Oak HC/FT
With: Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite, Lachy Groom, SV Angel, Glade Brook, Emerson Collective
$70M
Series A · 2025-08 · led by Menlo Ventures (Anthology Fund)
With: Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, Fred Ehrsam
▸Investor roster escalated from Menlo (Series A) to General Catalyst/Oak HC/FT (B) to Index/Kleiner/Sequoia/Dimension (C), with OpenAI and Thrive re-upping each round — a sign of insider conviction, not just new money chasing a hot deal
▸The ~3x valuation jump in 7 months is anchored in real signed contracts with three major pharma companies, not narrative alone — a relatively rare revenue-adjacent signal in the AI-for-biology space
Founders
Joshua Meier CEO
Previously Chief AI Officer at Absci; earlier a researcher at Facebook/Meta AI Research working on protein language models
Jack Dent President
Co-founder, President
Matt McPartlon CTO
Co-founder, CTO
Reality · Working here
Signals & Risks
Editorial ✎
Good fit for
· Structural biology / computational chemistry researchers — the moat here is model quality, and this is where a PhD converts directly into product impact
· Engineers who want genuinely high-stakes ML — customers are Lilly/Pfizer/Novartis, and model predictions feed real drug-pipeline decisions, not demos
· People comfortable with long feedback loops — drug discovery validation cycles run in years, not the fast dashboards of a typical startup
Not for
· Anyone who needs near-term, visible commercial certainty — this is still a model-capability and pharma-partnership story, far from proven clinical success
· Anyone who wants a steady pace — valuation and headcount are both in rapid expansion, and priorities can shift fast around big new contracts
Ask in the interview
1. Are the Lilly/Pfizer/Novartis deals early-access-plus-custom-model licenses, or do they carry milestone/success-based payments? That determines how sticky the revenue really is
2. After a ~3x valuation jump in 7 months, what happens to the team and cap table if the next round doesn't show the same slope of progress?
3. What's the retention plan for core research talent (especially founders with OpenAI ties), and how is 'key-person dependency' risk being managed?
Data changelog
Community corrections → editorial review → applied, fully on the record
data as of 2026-07 · Source: Sum of reported rounds: $70M Series A (2025-08) + $130M Series B (2025-12) + $400M Series C (2026-07) ↗
data as of 2026-07 · Source: IntuitionLabs coverage of Chai Discovery Series C ↗
data as of 2026-07 · Source: IntuitionLabs / Law360 coverage of Chai Discovery Series C ↗
Want to talk about this company?
Community members may work here or have interviewed — corrections and additions welcome too
Join the discussion